Intelligence / Healthtech / New Clinical Trials / PharmaResearch Co.,Ltd
PharmaResearch Co.,Ltd
3 Nov 2026: Trial registered · Clinical Evaluation of Dual-Plane Technique PN-Based Treatment for Horizontal Neck Lines Using DNA Fragment Opmizing Technology Polynucleotide (DOT PN). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 3 Nov 2026
- Title
- Clinical Evaluation of Dual-Plane Technique PN-Based Treatment for Horizontal Neck Lines Using DNA Fragment Opmizing Technology Polynucleotide (DOT PN)
- Conditions
- Skin Aging, Horizontal Neck Lines
- Study Type
- Observational
- Status
- Not Yet Recruiting
- Countries
- Malaysia, Singapore, Thailand
- Country
- Malaysia
- Reference
- NCT07912879
- Location
- Malaysia, Singapore, Thailand
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at PharmaResearch Co.,Ltd
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for PharmaResearch Co.,Ltd in our registers.
More from Malaysia
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.